Moreover, we summarize the current state of clinical investigation of LAG-3 targeting molecules in melanoma and discuss the position of dual checkpoint inhibition with anti-LAG-3 plus anti-PD-1 antibodies in the arsenal of current melanoma therapies. This evidence concerns the gene LAG3 and melanoma.